Originally published by our sister publication Pharmacy Practice News
By Gina Shaw
In the wake of the FDA’s Feb. 21, 2025 announcement declaring an end to the semaglutide (Ozempic/Wegovy, Novo Nordisk) shortage, stakeholders in the compounding arena offered their take on the agency’s decision and how it may affect patients’ ability to access—and afford—the blockbuster weight-loss medication.